BetterLife Pharma is an emerging biotechnology company focused on developing and commercializing patient-friendly compounds to treat neuro-psychiatric and neurological disorders.

Our vision is to take the fear out of psychedelics by producing non-hallucinogenic medicines that will be the solutions to treat the wide range of unmet mental health conditions like anxiety, depression, PTSD, & migraine headaches.

Fulfilling our responsibility for healthy and sound minds

Our Aim

Bring the most amount of good to the greatest number of people by delivering medicines to the market in most efficient and effective way.

Our Foundation

Optimize a science, and evidence driven approach to develop solutions for the variety of unmet mental and behavioural needs.

Our Construct

Harness ongoing care, dedication, and commitment to cultivate synergy in delivering access, choices, and opportunities for a better life.

Burdens call for alternatives in the landscape of options ….

Societal strains, alarming & intensifying, ring for alternatives
Reminders for expedited medical solutions are mounting
Covid Mental Strain
0 %
US Adults Are Dealing with Anxiety & Depression1
Adult with Depression
0 %
Do Not Receive Mental Health Treatment2
Mental Health Spending
$ 0 Billion
Increase In Anxiety & Depression In Adults3

BetterLife Pharma’s lead product, 2-Bromo-LSD (BETR-001), is a second-generation lysergic acid diethylamide (“LSD”) derivative molecule that mimics the projected therapeutic properties of LSD without causing its undesirable side effects such as hallucinations. As a non-psychedelic, BETR-001 has the potential benefits without the hallucination related use restrictions and regulatory hurdles imposed on psychedelics.

Time-to-market solutions lean on key considerations

CSA Schedule 1 Drug NoYesYesYes
Multiple Formal Human StudiesYesYesYesYes
Hallucinogenic EffectsNoYesYesLow/No
USDOJ List 1 Precursors NoYesYesYes
UN Convention Illicit Drug NoYesYesYes
Patient Self-AdministeredYesNoNoNo
Regulatory Hurdle(s)LowHighHighHigh

BETR-001 is a potential new therapy to treat debilitating psychiatric disorders with high unmet need, such as treatment-resistant depression and post-traumatic stress disorder; as well as severe neurological disorders such as cluster headaches. This compound represents a promising alternative to existing treatments but also compares favorably to other upcoming solutions.


BetterLife Pharma Inc. (BETR:CNX)

BetterLife Pharma Inc – Ordinary Shares (BETRF)


Contact Us
Working together to Build a BetterLife for all.

Working to Build a BetterLife, with innovate medicines.


Our work delivers patient-friendly medicines to rejuvenate and restore the health of the mind and the body.

Email us:

Follow us: